{"filing":{"accession_number":"0001193125-26-386662","cik":"0000718937","ticker":"STAA","company_name":"STAAR SURGICAL CO","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"staa-20260909.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/718937/000119312526386662/staa-20260909.htm"},"events":[{"id":32441,"run_id":29804,"accession_number":"0001193125-26-386662","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"David Bailey was appointed Chief Commercial Officer of STAAR Surgical effective September 8, 2026, reporting to the CEO and joining the executive committee. His compensation package includes a base salary of CHF 462,825, target bonus of 60%, initial equity grant of $850,000 in RSUs, and a 2026 long-term incentive award of $1,400,000. Bailey, a former CEO and President of International Operations, is expected to play a strategic role in the company's commercial execution and growth initiatives.","company_name":"STAAR SURGICAL CO","ticker":"STAA","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35610,"accession_number":"0001193125-26-386662","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"David Bailey was appointed Chief Commercial Officer of STAAR Surgical effective September 8, 2026. The filing discloses his appointment to this executive officer role, his compensation package (base salary of CHF 462,825, target bonus of 60%, initial equity grant of $850,000 in RSUs, and 2026 long-term incentive award of $1,400,000), and his reporting relationship to the CEO. This is a material executive appointment of a former CEO returning to lead a key commercial function, as evidenced by the press release highlighting his strategic importance to the company's growth initiatives.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T10:01:49.914394+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35611,"accession_number":"0001193125-26-386662","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of David Bailey as Chief Commercial Officer, a named executive position reporting to the CEO and joining the executive committee. Although Bailey previously served as President and CEO (2001–2008) and President of International Operations (2008–2011), the principal disclosed action is his appointment to a new executive role. The press release emphasizes his strategic importance to revenue growth and commercial execution, making this a material executive appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T10:01:49.914394+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35610,"accession_number":"0001193125-26-386662","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"David Bailey was appointed Chief Commercial Officer of STAAR Surgical effective September 8, 2026. The filing discloses his appointment to this executive officer role, his compensation package (base salary of CHF 462,825, target bonus of 60%, initial equity grant of $850,000 in RSUs, and 2026 long-term incentive award of $1,400,000), and his reporting relationship to the CEO. This is a material executive appointment of a former CEO returning to lead a key commercial function, as evidenced by the press release highlighting his strategic importance to the company's growth initiatives.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T10:01:49.914394+00:00","company_name":"STAAR SURGICAL CO","ticker":"STAA","filing_date":"2026-09-09"},{"id":35611,"accession_number":"0001193125-26-386662","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of David Bailey as Chief Commercial Officer, a named executive position reporting to the CEO and joining the executive committee. Although Bailey previously served as President and CEO (2001–2008) and President of International Operations (2008–2011), the principal disclosed action is his appointment to a new executive role. The press release emphasizes his strategic importance to revenue growth and commercial execution, making this a material executive appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T10:01:49.914394+00:00","company_name":"STAAR SURGICAL CO","ticker":"STAA","filing_date":"2026-09-09"}]}